Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice

Acta Neuropsychiatrica

Volumn 24, Issue 5, 2012, Pages 296-300

  Krass, Maarja ^a   Rünkorg, Kertu ^a   Vasar, Eero ^a   Volke, Vallo ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

anxiety; cortisol; neuroendocrinology; stress

Indexed keywords

CORTICOSTERONE; EXENDIN 4; GLUCOSE; IMIPRAMINE; LIRAGLUTIDE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; GLUCOSE BLOOD LEVEL; IMMOBILIZATION; LIGHT DARK CYCLE; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; SWIMMING;

EID: 84866483520     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2012.00648.x     Document Type: Article

References (17)

1. Drucker DJ., The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
2. Williams DL., Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology 2009; 150: 2997-3001.
3. Tang-Christensen M, Larsen PJ, Goke R, et al., Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-R856.
4. During MJ, Cao L, Zuzga DS, et al., Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179.
5. Kinzig KP, D'Alessio DA, Herman JP, et al., CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003; 23: 6163-6170.
6. Moller C, Sommer W, Thorsell A, Rimondini R, Heilig M., Anxiogenic-like action of centrally administered glucagon-like peptide-1 in a punished drinking test. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 119-122.
7. Gulec G, Isbil-Buyukcoskun N, Kahveci N., Effects of centrally-injected glucagon-like peptide-1 on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat. Neuropeptides 2010; 44: 285-291.
8. MacLusky NJ, Cook S, Scrocchi L, et al., Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology 2000; 141: 752-762.
9. Gil-Lozano M, Perez-Tilve D, Varez-Crespo M, et al., GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 2010; 151: 2629-2640.
10. Kastin AJ, Akerstrom V., Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27: 313-318.
11. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR., Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011; 152: 3103-3112.
12. Crawley J, Goodwin FK., Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980; 13: 167-170.
13. Porsolt RD, Bertin A, Jalfre M., Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-336.
14. Volke V, Wegener G, Bourin M, Vasar E., Antidepress ant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2- trifluoromethylphenyl)-imidazole in mice. Behav Brain Res 2003; 140: 141-147.
15. Strawn JR, D'Alessio DA, Keck PE Jr, Seeley RJ., Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder. J Psychiatr Res 2008; 42: 787-789.
16. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL., Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 2005; 146: 3748-3756.
17. Porter DW, Kerr BD, Flatt PR, Holscher C, Gault VA., Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes Metab 2010; 12: 891-899.